Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cephapirin-induced neutropenia.

C Vidal Pan1, A González Quintela, J Román García

  • 1Services of Allergy, Clinica Puerta de Hierro, Universidad Autónoma, Madrid, Spain.

Chemotherapy
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SEAIC Specialty Forum: Analysis of the Current Situation of Allergology in Spain and Outlook for the Future.

Journal of investigational allergology & clinical immunology·2019
Same author

Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Effect of intratympanic dimethyl sulphoxide (DMSO) in an in vivo model of cisplatin-related ototoxicity.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2014
Same author

Determinants of fat-soluble vitamin status in patients aged 65 years and over.

European journal of clinical nutrition·2013
Same author

Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome.

Renal failure·2013
Same author

Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease.

Renal failure·2013
Same journal

Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy.

Chemotherapy·2026
Same journal

Pseudoprogression of a head and neck cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy: a case report and review of the literature.

Chemotherapy·2026
Same journal

Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case series.

Chemotherapy·2026
Same journal

Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis.

Chemotherapy·2026
Same journal

Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?

Chemotherapy·2026
Same journal

Expression of Concern.

Chemotherapy·2026
See all related articles

High doses or prolonged use of cephapirin can cause reversible neutropenia, a serious blood disorder. Hematologic monitoring is recommended during extended cephapirin therapy to prevent adverse effects.

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Cephapirin is an antibiotic used in clinical settings.
  • Neutropenia is a condition characterized by an abnormally low level of neutrophils.

Purpose of the Study:

  • To investigate the incidence and characteristics of cephapirin-induced neutropenia.
  • To identify risk factors associated with the development of neutropenia during cephapirin treatment.

Main Methods:

  • Retrospective analysis of 132 patients treated with cephapirin.
  • Comparison of demographic and treatment data between patients who developed neutropenia and those who did not.
  • Statistical analysis to determine significant risk factors.

Main Results:

Related Experiment Videos

  • Five cases (3.5%) of reversible neutropenia, including 3 cases of agranulocytosis, were observed.
  • Neutropenia was associated with higher daily and total doses, and longer duration of cephapirin therapy (p < 0.05).
  • The incidence of neutropenia exceeded 26.3% when the total dose surpassed 90g (p < 0.001).

Conclusions:

  • Cephapirin can induce reversible neutropenia, particularly with high doses and prolonged administration.
  • Hematologic monitoring is advisable for patients receiving long-term or high-dose cephapirin therapy.
  • Early detection and intervention are crucial for managing antibiotic-induced hematologic disorders.